Dyne Therapeutics, Inc.
NASDAQ:DYN · NASDAQ Global Select
+$0.38 today
Vol 4.27M · Avg 1.71M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-45.9%
avg -48.4%
ROIC
-41.0%
avg -52.6%
ROA
-37.6%
avg -43.8%
Analysis
ROA is currently the strongest return metric at -37.6% versus its period average of -43.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John G. Cox | Chief Executive Officer, President & Director | $1.14M | — | 63 | $368,151.00 | 0.22% |
Johanna Friedl-Naderer | Chief Commercial Officer | $842,754.00 | — | 58 | $154,208.00 | 0.09% |
Douglas Kerr | Chief Medical Officer | $748,065.00 | — | 59 | $169,155.00 | 0.10% |
Oxana Beskrovnaya | Chief Innovation Officer | $740,475.00 | — | 65 | $195,840.00 | 0.12% |
Erick J. Lucera | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer | $726,892.00 | — | 58 | $123,925.00 | 0.07% |
Vikram Ranade | Chief Business Officer | $662,344.00 | — | — | $59,665.00 | 0.04% |
James Bilotta | Chief Digital & Information Officer | — | — | — | $0.00 | <0.01% |
Debra Feldman | Chief Regulatory Affairs Officer | — | — | 55 | — | — |
Lucia Celona | Chief Human Resource Officer | — | — | 60 | — | — |
Monica Fay | Chief Medical Affairs Officer | — | — | — | — | — |
Rajesh Manchanda | Chief Technical Officer | — | — | 59 | — | — |
Jose Juves | Chief Corporate & Patient Affairs Officer | — | — | — | — | — |
Daniel Wilson | Senior Vice President & Head of Legal | — | — | 54 | — | — |
Axel Wiest | Senior VP and Head of Portfolio Strategy & Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$1.19M
Sells
79
$54.97M
Net Sentiment
$53.78M
Net selling
Most Active
Rhodes Jason P
48 transactions
1–10 of 87
Analysis
Insiders reported 8 buys worth $1.19M and 79 sells worth $54.97M over the last 12 months. That adds up to net selling of $53.78M. Rhodes Jason P was the most active insider with 48 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -22.8% | +11.6% (15yr)3 analysts |
| Revenue | N/A | N/A | +554.7% | +3.4% (15yr)4 analysts |
| Net Income | N/A | N/A | -16.9% | +11.8% (15yr)4 analysts |
| EBIT | N/A | N/A | -55.2% | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +554.7% over three years. Forward estimates point to Net Income at +11.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.17B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.41B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.41B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$5.27B
Celcuity Inc.
NASDAQ:CELC
$4.18B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.17B
Telix Pharmaceuticals Limited
NASDAQ:TLX
$3.40B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.71B
Ascentage Pharma Group International
NASDAQ:AAPG
$404.16M
Who manages DYN?
Dyne Therapeutics, Inc. (DYN) lists 14 active executives. The top listed executive is Oxana Beskrovnaya, Chief Innovation Officer.
Are DYN insiders buying or selling?
Recent insider activity shows net selling of $24.62M.
Explore More
Continue the stock analysis
Jump to another research area for this company.